Mannitol Vioser (Mannitol)

Mannitol increases the osmolarity of the extracellular fluid after intravenous infusion. This osmotic gradient pulls water from cells and tissues into the bloodstream and renal tubules, producing diuresis and reducing swelling in the brain and eye.

The dose of Mannitol Vioser is individualized by the prescribing clinician based on the patient’s condition, weight, and response. Specific dosing regimens are not provided here and should follow the prescriber’s orders and institutional protocols.

Safety data for Mannitol Vioser in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Mannitol Vioser, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mannitol is a widely used osmotic diuretic that provides rapid plasma osmolarity increase, whereas alternatives such as hypertonic saline may have a slower onset and different electrolyte effects. Mannitol’s well‑characterized renal clearance and predictable diuretic response make it a preferred choice in many neurosurgical and renal‑protective protocols.

Mannitol Vioser should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the product, and inspect the vial for particulate matter before use.

Mannitol Vioser is given by intravenous infusion. The solution is typically diluted with compatible IV fluids and infused over a period determined by the prescriber, often ranging from a few minutes to several hours, depending on the clinical indication and patient tolerance.

Serious risks include acute renal failure, pulmonary edema, severe electrolyte disturbances (such as hyponatremia or hyperkalemia), and rare anaphylactic reactions. Patients should be closely monitored for changes in renal function, fluid balance, and respiratory status during therapy.

Mannitol Vioser is contraindicated in patients with anuria, severe renal impairment, active intracranial hemorrhage, uncontrolled heart failure, or severe dehydration. It should also be avoided in individuals with known hypersensitivity to mannitol or any component of the formulation.